Gain Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GANX | VYGR | ALEC | ADXN | ATHE | PMN | |
|---|---|---|---|---|---|---|
| Market cap | 48.44M | 115.23M | 254.58M | 5.33M | 46.58M | 31.57M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.6 | -1.5 | -3.1 | -60.9 | -2.9 | -0.8 |
| Price/book | 4.3 | 0.7 | -25.6 | 1.4 | 1.5 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −41.58% | −55.69% | +75.38% | −65.26% | −30.29% | −63.90% |
| Today | −3.48% | +2.19% | +11.22% | +1.27% | −1.21% | +3.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GANX news ›Gain Therapeutics (GANX) Set to Post Earnings on Wednesday
Posted by Sarita Garza on Nov 4th, 2026 Gain Therapeutics (NASDAQ:GANX – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus…
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Details of the poster and presentation are as follows: Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 (Rexaceract) in People with Parkinson’s Disease E-Poster Number : 753 Presentation Date : October 7, 2026…
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnolo... Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference…
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026…
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event. About the Maxim Growth Summit This prestigious event brings together…
H.C. Wainwright Reaffirms Their Buy Rating on Gain Therapeutics (GANX)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Gain Therapeutics today and set a price target of $8.00. According to TipRanks, Selvaraju is a 4-star analyst with an average return of 9.5% and a 45.11% success rate.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- manilatimes.net2
- stocktitan.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.